Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
Our findings indicate that pre-existing IN and RT DRM, including low-abundance and secondary/polymorphic variants, did not compromise the virological efficacy of dolutegravir-based triple therapy in ART-naïve individuals, supporting the high resistance barrier of dolutegravir and the lack of need for baseline resistance testing.
Institutions
- Hospital Universitario de Canarias (ES)
- Instituto de Salud Carlos III (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital General Universitario De Valencia (ES)
- Hospital Universitario de Valme (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1093/jac/dkag080
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00